Evidence map›Paper›PMID 29667444›Full record

ArticleDrug delivery2018

AKT2 siRNA delivery with amphiphilic-based polymeric micelles show efficacy against cancer stem cells.

Diana Rafael, Petra Gener, Fernanda Andrade, Joaquin Seras-Franzoso, Sara Montero, Yolanda Fernández, Manuel Hidalgo, Diego Arango, Joan Sayós, Helena F Florindo and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug delivery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

Diana Rafaela Research Institute for Medicines and Pharmaceutical Sciences, Faculdade de Farmácia , Universidade de Lisboa (iMed.ULisboa) , Lisbon , Portugal.
Petra Generb Drug Delivery and Targeting Group , Molecular Biology and Biochemistry Research Centre for Nanomedicine (CIBBIM-Nanomedicine), Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona , Barcelona , Spain.
Fernanda Andradec Networking Research Centre for Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN), Instituto de Salud Carlos III , Zaragoza , Spain.
Joaquin Seras-Franzosob Drug Delivery and Targeting Group , Molecular Biology and Biochemistry Research Centre for Nanomedicine (CIBBIM-Nanomedicine), Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona , Barcelona , Spain.
Sara Monterob Drug Delivery and Targeting Group , Molecular Biology and Biochemistry Research Centre for Nanomedicine (CIBBIM-Nanomedicine), Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona , Barcelona , Spain.
Yolanda Fernándezb Drug Delivery and Targeting Group , Molecular Biology and Biochemistry Research Centre for Nanomedicine (CIBBIM-Nanomedicine), Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona , Barcelona , Spain.
Manuel Hidalgoe Division of Hematology and Oncology , Rosenberg Clinical Cancer Center Beth Israel Deaconess Medical Center , Boston , MA , USA.
Diego Arangof Biomedical Research in Digestive Tract Tumors, CIBBIM-Nanomedicine, Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona , Barcelona , Spain.
Joan Sayósg Immune Regulation and Immunotherapy , CIBBIM-Nanomedicine, Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona , Barcelona , Spain.
Helena F Florindoa Research Institute for Medicines and Pharmaceutical Sciences, Faculdade de Farmácia , Universidade de Lisboa (iMed.ULisboa) , Lisbon , Portugal.
Ibane Abasolob Drug Delivery and Targeting Group , Molecular Biology and Biochemistry Research Centre for Nanomedicine (CIBBIM-Nanomedicine), Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona , Barcelona , Spain.
Simó Schwartzb Drug Delivery and Targeting Group , Molecular Biology and Biochemistry Research Centre for Nanomedicine (CIBBIM-Nanomedicine), Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona , Barcelona , Spain.ORCID http://orcid.org/0000-0001-8297-7971
Mafalda Videiraa Research Institute for Medicines and Pharmaceutical Sciences, Faculdade de Farmácia , Universidade de Lisboa (iMed.ULisboa) , Lisbon , Portugal.
Universitat Autònoma de Barcelona · ESUniversity of Lisbon · PTBeth Israel Deaconess Medical Center · USInstituto de Salud Carlos III · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Development of RNA interference-based therapies with appropriate therapeutic window remains a challenge for advanced cancers. Because cancer stem cells (CSC) are responsible of sustaining the metastatic spread of the disease to distal organs and the progressive gain of resistance of advanced cancers, new anticancer therapies should be validated specifically for this subpopulation of cells. A new amphihilic-based gene delivery system that combines Pluronic

Indexed as

Antineoplastic AgentsBreast NeoplasmsCell Line, TumorDrug Delivery SystemsFemaleGene Transfer TechniquesHumansMCF-7 CellsMicellesNanomedicineNeoplastic Stem CellsPoloxamerPolyethyleneiminePolymersProto-Oncogene Proteins c-aktRNA InterferenceAKT2 protein, humanAntineoplastic AgentsMicellesPoloxamerPolyethyleneiminePolymersProto-Oncogene Proteins c-aktRNA, Small InterferingAKT2cancer stem cellsgene deliveryPluronic®Polymeric micelles

Identifiers

PMID29667444
PMCPMC6060707
OpenAlexW2801608258

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.